𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer

✍ Scribed by Rosalia, Rodney A; Arenas-Ramirez, Natalia; Bouchaud, Grégory; Raeber, Miro E; Boyman, Onur

Book ID
127335218
Publisher
Elsevier Science
Year
2014
Tongue
English
Weight
546 KB
Volume
23
Category
Article
ISSN
1367-5931

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The requirements for successful immunoth
The requirements for successful immunotherapy of intraperitoneal cancer using interleukin-2 and lymphokine-activated killer cells
✍ Reyer T. Ottow; Alexander M. M. Eggermont; E. Philip Steller; Paul H. Sugarbaker 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 907 KB

In a significant proportion of patients with gastrointestinal and ovarian malignancy the peritoneal cavity is a prominent site at which surgical treatment fails. Adjuvant treatments directed at this site should be investigated in an attempt to improve survival in patients with these cancers. In the

Immunotherapy of advanced renal cell can
Immunotherapy of advanced renal cell cancer using subcutaneous recombinant interleukin-2 and interferon-α
✍ H. Kirchner; W. Riese; E. Allhoff; H. Poliwoda; J. Atzpodien 📂 Article 📅 1991 🏛 Springer-Verlag 🌐 English ⚖ 450 KB

The combined administration of subcutaneous recombinant human interleukin-2 (rIL-2) and interferon-a (rIFN-~) was studied in a phase II trial on patients with advanced progressive renal cell cancer. Safety, tolerance and clinical response rate of this outpatient treatment protocol were assessed in 2